Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Stoke Therapeutics (STOK) Profit After Tax (2022 - 2025)

Stoke Therapeutics has reported Profit After Tax over the past 4 years, most recently at -$57.9 million for Q4 2025.

  • For Q4 2025, Profit After Tax fell 452.7% year-over-year to -$57.9 million; the TTM value through Dec 2025 reached -$6.9 million, up 92.26%, while the annual FY2025 figure was -$6.9 million, 92.26% up from the prior year.
  • Profit After Tax for Q4 2025 was -$57.9 million at Stoke Therapeutics, down from -$38.3 million in the prior quarter.
  • Over five years, Profit After Tax peaked at $112.9 million in Q1 2025 and troughed at -$57.9 million in Q4 2025.
  • A 4-year average of -$18.9 million and a median of -$25.7 million in 2022 define the central range for Profit After Tax.
  • On a YoY basis, Profit After Tax climbed as much as 527.99% in 2025 and fell as far as 452.7% in 2025.
  • Year by year, Profit After Tax stood at -$25.7 million in 2022, then decreased by 5.08% to -$27.0 million in 2023, then surged by 61.12% to -$10.5 million in 2024, then crashed by 452.7% to -$57.9 million in 2025.
  • Business Quant data shows Profit After Tax for STOK at -$57.9 million in Q4 2025, -$38.3 million in Q3 2025, and -$23.5 million in Q2 2025.